title: Diagnosis of patients with suspected chronic hepatitis C infection.
abstract: The current optimal approach to detecting hepatitis C virus (HCV) infection involves screening people for risk factors and only testing selected individuals at risk. Blood transfusion from infectious donors, unsafe therapeutic injection practices, and illegal intravenous drug use have been the predominant modes of transmission of HCV infection. Virological markers that are currently used for the clinical management of patients with hepatitis C include serologic assays (ELISA or immunoblot assays), which detect specific antibodies (IgG) to HCV, and virological assays, which detect serum HCV RNA, by highly sensitive qualitative and quantitative techniques. The applicability of these tests is for the diagnoses and monitoring of the treatment but they have no role in the assessment of disease severity or prognosis. Patients diagnosed with HCV infection must be educated in order to avoid the spread of the disease to other people.
authors: Sección Hepatología, Hospital Italiano de Buenos Aires-Argentina, Ciudad de Buenos Aires, Argentina. adrian.gadano@hospitalitaliano.org.ar
authors: Adrián
authors: A
authors: Gadano
authors: Omar
authors: O
authors: Galdame
authors: Sebastián
authors: S
authors: Marciano
mesh_terms: D015415:Biomarkers / Q000097:blood; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology; D018937:Hepatitis C Antibodies / Q000097:blood; D018936:Hepatitis C Antigens / Q000097:blood; D019698:Hepatitis C, Chronic / Q000175:diagnosis* / Q000453:epidemiology / Q000635:transmission; D006801:Humans; D008403:Mass Screening / Q000379:methods; D017410:Practice Guidelines as Topic; D011237:Predictive Value of Tests; D012367:RNA, Viral / Q000097:blood; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D015415:Biomarkers; D018937:Hepatitis C Antibodies; D018936:Hepatitis C Antigens; D012367:RNA, Viral